Genome & Company

Genome & Company is a global biopharmaceutical company that focuses on developing microbiome pharmaceuticals, consumer products and novel immune checkpoint inhibitors based on real-world clinical data and Multi-Omics analytic technology. Since its establishment in 2015, as a global leader in the field of microbiome for immuno-oncology and novel drug discovery for immuno-oncology target, Genome & Company has been collaborating with global pharmaceutical companies, research institutions and hospitals in Korea based on the “Bed-to-Bench” approach (real-world clinical data driven R&D strategy) of GNOCLE™, a platform for discovering novel drug candidates. Genome & Co strives to accelerate the development of innovative medicine to fulfill the medical unmet needs through microbiome therapeutics and novel drug target antibodies.(Multi-Omics). 2015,(GNOCLE™)'Bed-to-Bench'().